BioNexus Gene Lab Corp. Increase (Decrease) in Accounts and Other Receivables
BioNexus Gene Lab Corp. (BGLC) reported Increase (Decrease) in Accounts and Other Receivables of -$243.02 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2026-05-15
- BioNexus Gene Lab Corp. increase (decrease) in accounts and other receivables for the quarter ending 2026-03-31 was -$243.02K, a 315.79% decline year-over-year.
- BioNexus Gene Lab Corp. increase (decrease) in accounts and other receivables for the quarter ending 2025-12-31 was -$944.70K, a 32924.91% decline year-over-year.
- BioNexus Gene Lab Corp. increase (decrease) in accounts and other receivables for the quarter ending 2025-09-30 was -$206.47K.
- BioNexus Gene Lab Corp. increase (decrease) in accounts and other receivables for the quarter ending 2025-06-30 was $255.72K, a 122.15% increase year-over-year.
- BioNexus Gene Lab Corp. increase (decrease) in accounts and other receivables for fiscal 2025 was -$782.84K.
- BioNexus Gene Lab Corp. increase (decrease) in accounts and other receivables for fiscal 2024 was -$147.76K.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 3 month as first filed | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | -$243.02K 10-Q · filed 2026-05-15 | -$1.19M derived: sum of 2 quarters · filed 2026-05-15 | -$1.39M derived: sum of 3 quarters · filed 2026-05-15 | -$1.14M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-12-31 | -$944.70K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$1.15M derived: sum of 2 quarters · filed 2026-04-14 | -$895.46K derived: sum of 3 quarters · filed 2026-04-14 | -$782.84K 10-K · filed 2026-04-14 | |
| 2025-09-30 | -$206.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $49.24K derived: sum of 2 quarters · filed 2025-11-14 | $161.86K 10-Q · filed 2025-11-14 | $164.74K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-06-30 | $255.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $368.33K 10-Q · filed 2025-08-18 | $371.21K derived: sum of 3 quarters · filed 2026-05-15 | $217.93K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-03-31 | $112.61K 10-Q · filed 2026-05-15 | -$112.61K 10-Q · filed 2025-05-15 | $115.49K derived: sum of 2 quarters · filed 2026-05-15 | -$37.79K derived: sum of 3 quarters · filed 2026-05-15 | $77.33K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $2.88K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$150.40K derived: sum of 2 quarters · filed 2026-04-14 | -$35.29K derived: sum of 3 quarters · filed 2026-04-14 | -$147.76K 10-K · filed 2026-04-14 | |
| 2024-09-30 | -$153.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$38.16K derived: sum of 2 quarters · filed 2025-11-14 | -$150.64K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $115.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $2.64K 10-Q · filed 2025-08-18 | |||
| 2024-03-31 | -$112.47K 10-Q · filed 2025-05-15 | ||||
| 2023-09-30 | -$151.38K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2024-03-26 | -$170.16K derived: sum of 2 quarters · filed 2024-03-26 | -$505.67K 10-Q/A · filed 2024-03-26 | ||
| 2023-06-30 | -$18.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-16 | -$354.29K 10-Q · filed 2023-08-16 | |||
| 2023-03-31 | -$335.51K 10-Q · filed 2023-05-09 | ||||
| 2022-09-30 | -$112.24K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2024-03-26 | -$308.08K derived: sum of 2 quarters · filed 2024-03-26 | -$638.40K 10-Q/A · filed 2024-03-26 | ||
| 2022-06-30 | -$195.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-16 | -$526.16K 10-Q · filed 2023-08-16 | |||
| 2022-03-31 | -$330.32K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |